Oppenheimer & Co
IMRX icon

Oppenheimer & Co’s Immuneering IMRX Stock Holding History

Oppenheimer & Co’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$90.1K Sell
22,000
-13,000
-37% -$61.4K ﹤0.01% 1714
2026
Q2 		$175K Buy
35,000
+1,000
+3% +$5.06K ﹤0.01% 1674
2026
Q1 		$179K Buy
+34,000
New +$174K ﹤0.01% 1593

Other funds holding IMRX

PVG Asset Management
PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return
Wealth Effects
Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return
Flower City Capital
Flower City Capital Pittsford, New York $234M AUM 15.69% 1-Year Est. Return
Berman McAleer
Berman McAleer Timonium, Maryland $862M AUM 13.92% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Future Financial Wealth Management
Future Financial Wealth Management Cincinnati, Ohio $163M AUM 15.03% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Park Avenue Securities
Park Avenue Securities New York $16.4B AUM 18.52% 1-Year Est. Return
Focus Financial Network
Focus Financial Network Minneapolis, Minnesota $3.3B AUM 21.52% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

Oppenheimer & Co's IMRX Position: Q3 2026 in Review

Oppenheimer & Co reduced its Immuneering (IMRX) stake by 37% in Q3 2026, selling an estimated $61.4K and leaving 22,000 shares worth $90.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

Oppenheimer & Co first reported a position in IMRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $179K in Q1 2026. 18 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Oppenheimer & Co held 22,000 shares of Immuneering worth $90.1K as of Q3 2026.
  • Oppenheimer & Co sold 13,000 Immuneering shares in Q3 2026, an estimated $61.4K.
  • Immuneering made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1714 holding.
  • Oppenheimer & Co first reported a position in Immuneering in Q1 2026 and has held it in 3 quarters since.
  • Oppenheimer & Co's Immuneering position peaked at $179K in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.